OMEROS CORP - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Omeros Corporation on August 9, 2013. The filing serves to announce the company's financial results for the three and six months ended June 30, 2013, via a press release incorporated as Exhibit 99.1.
Key Financial Metrics
The provided text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are detailed in the referenced press release (Exhibit 99.1), which is not included in the input text.
Material Changes
The filing text does not provide specific data regarding material changes versus prior comparable periods. It only confirms the issuance of results for the specified periods.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, forward-looking guidance, specific risk factors, or details on contingencies and unusual items. The report explicitly states that the information contained herein shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and shall not be incorporated by reference into other SEC filings.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated August 9, 2013) for actual financial figures.
- Verify the specific revenue and net loss figures for the three and six months ended June 30, 2013.
- Check the press release for updates on clinical trial progress or regulatory milestones, which are typical for this biopharmaceutical company.
- Confirm cash position and burn rate details from the full financial statements referenced in the exhibit.